Fig. 3.
Addition of a PD-1 inhibitor to CHP-NY-ESO-1/poly-ICLC in the NY-ESO-1-transfected tumor inoculation mouse model. BALB/c mice subcutaneously inoculated with 1 × 106 human NY-ESO-1-transfected murine colon cancer CT26 cells were treated with anti-PD-1 mAb (clone RMP1-14) alone, CHP-NY-ESO-1/poly-ICLC, or CHP-NY-ESO-1/poly-ICLC/anti-PD-1 mAb (n = 4 per group). CHP-NY-ESO-1 (40 μg/mouse) and poly-ICLC (50 μg/mouse) were administered subcutaneously on days 1 and 7. The anti-PD-1 monoclonal antibody (clone RMP1-14, 150 μg/mouse) was administered intraperitoneally on days 1, 4, 7, 9, 13, 16, and 19. Compared with the non-treatment group, only the CHP-NY-ESO-1/poly-ICLC/anti-PD-1 mAb group showed tumor growth suppression (not statistically significant by the Mann–Whitney U test). The mouse model shows tumor protection activity in NY-ESO-1-expressing tumor inoculation